IVIG use in renal insufficiency or transplantation

U.S. Pharmacist

Volumn 35, Issue 10, 2010, Pages

  Williams, Amy K ^a,d   Ward, Leah G ^b   Bhatt, Valkal K ^b,c  

^a Walgreens   (United States)

^b MAYO CLINIC   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CARIMUNE; GAMMAR P; GLUCOSE; GLYCINE; HLA ANTIBODY; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; MALTOSE; SORBITOL; STABILIZING AGENT; SUCROSE; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; AGE DISTRIBUTION; ANTIBODY TITER; ARTHRALGIA; BACKACHE; CHILL; DEHYDRATION; DIABETES MELLITUS; DRUG FEVER; DRUG FORMULATION; DRUG USE; DRUG WITHDRAWAL; FATIGUE; HIP PAIN; HUMAN; HYDRATION; HYPOVOLEMIA; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; PARAPROTEINEMIA; REVIEW; SEPSIS; THORAX PAIN;

EID: 78049308016     PISSN: 01484818     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Review

References (19)

1. MICROMEDEX online database [subscription required]. Greenwood Village, CO: Thomson Reuters (Healthcare), Inc. www.thomsonhc.com. Accessed September 14, 2010.
2. Leong H, Stachnik J, Bonk ME, Matuszewski KA. Unlabeled uses of intravenous immune globulin. Am J Health Syst Pharm. 2008;65:1815-1824.
3. Ratko TA, Burnett DA, Foulke GE, et al. Recommendations for off-label use of intravenously administered immunoglobulin preparations. University Hospital Consortium Expert Panel for Off-Label Use of Polyvalent Intravenously Administered Immunoglobulin Preparations. JAMA. 1995;273:1865-1870.
4. Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2006;117(suppl 4):S525-S553.
5. American Society of Health-System Pharmacists. ASHP drug product shortages management resource center. www.ashp.org/DrugShortages/Current/. Accessed September 14, 2010.
6. Shah S. Practical considerations for the use of IGIV therapy: introduction. Am J Health Syst Pharm. 2005;62(16 suppl 3):S3-S4.
7. Flebogamma (immune globulin intravenous [human]) product information. Los Angeles, CA: Grifols Biologicals, Inc; January 2010.
8. Gamunex (immune globulin intravenous [human]) product information. Research Triangle Park, NC: Talecris Biotherapeutics Inc; October 2008.
9. Gammagard Liquid (immune globulin, intravenous [human]) product information. Westlake Village, CA: Baxter Healthcare Corp; October 2009.
10. Gammagard S/D (immune globulin intravenous [human]) product information. Westlake Village, CA: Baxter Healthcare Corp; December 2009.
11. Itkin YM, Trujillo TC. Intravenous immunoglobulin-associated acute renal failure: case series and literature review. Pharmacotherapy. 2005;25:886-892.
12. Shah S, Vervan M. Use of i.v. immune globulin and occurrence of associated acute renal failure and thrombosis. Am J Health Syst Pharm. 2005;62:720-725.
13. Chapman SA, Gilkerson KL, Davin TD, Pritzker MR. Acute renal failure and intravenous immune globulin: occurs with sucrose-stabilized, but not with d-sorbitol-stabilized, formulation. Ann Pharmacother. 2004;38:2059-2067.
14. Cayco AV, Perazella MA, Hayslett JP. Renal insufficiency after intravenous immune globulin therapy: a report of two cases and an analysis of the literature. J Am Soc Nephrol. 1997;8:1788-1794.
15. FDA. Dear doctor letter - important drug warning: immune globulin intravenous (human). November 13, 1998. www.fda.gov/BiologicsBloodVaccines/ SafetyAvailability/ucm105914.htm. Accessed September 14, 2010.
16. Renal insufficiency and failure associated with immune globulin Intravenous therapy - United States, 1985-1998. MMWR. 1999;48:518-521.
17. Darabi K, Abdel-Wahab O, Dzik WH. Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature. Transfusion. 2006;46:741-753.
18. Glotz D, Antoine C, Julia P, et al. Intravenous immunoglobulins and transplantation for patients with anti-HLA antibodies. Transpl Int. 2004;17:1-8.
19. Lee P, Zhu L, Terasaki PI, Everly MJ. HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Transplantation. 2009;88:568-574.